FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

By
Kathryn Wighton
July 2, 2026
3 min

Conexiant

At a Glance

Category	Detail
Condition	Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Key Mechanisms	CRISPR/Cas9 gene-edited cell therapy modifying hematopoietic stem and progenitor cells to increase fetal hemoglobin production.
Target Population	Patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
Care Setting	Clinical trials and authorized treatment centers across the US.

Key Highlights

Expanded indication for exagamglogene autotemcel (CASGEVY) to include younger patients.
Clinical trials showed reduction or elimination of vaso-occlusive crises in patients with SCD.
More than 75 treatment centers activated across the US for the therapy.
Warnings include neutrophil engraftment failure and hypersensitivity reactions.
Ongoing studies evaluating long-term safety and efficacy with follow-up of up to 15 years.

Guideline-Based Recommendations

Diagnosis

Diagnosis of sickle cell disease or transfusion-dependent beta thalassemia.

Management

Consider gene therapy for eligible patients aged 2 years and older.

Monitoring & Follow-up

Monitor for neutrophil and platelet engraftment, hypersensitivity reactions, and adverse reactions.

Risks

Potential for off-target genome editing and common adverse reactions such as mucositis and febrile neutropenia.

Patient & Prescribing Data

Approximately 5,500 additional pediatric patients in the US eligible for treatment.

All treated patients with SCD and TDT experienced grade 3 or 4 neutropenia and thrombocytopenia.

Clinical Best Practices

Engage in shared decision-making with families regarding treatment options.
Ensure thorough monitoring for adverse effects post-treatment.
Stay updated on ongoing clinical trial results for long-term safety and efficacy.